Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BERKELEY HEIGHTS, N.J., JAN. 08, 2026 (GLOBE NEWSWIRE) -- CORMEDIX THERAPEUTICS (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED AN ADDITION TO ITS EXECUTIVE LEADERSHIP TEAM AND UPDATES TO ITS BOARD OF DIRECTORS. CORMEDIX CEO JOSEPH TODISCO HAS SIGNED AN EXTENDED EMPLOYMENT CONTRACT, REAFFIRMING HIS LONG-TERM COMMITMENT TO THE ORGANIZATION. IN ADDITION TO HIS ROLE AS CEO, MR. TODISCO WILL ALSO ASSUME THE ROLE OF CHAIRMAN OF THE BOARD OF DIRECTORS, SUCCEEDING MYRON KAPLAN. MR. KAPLAN WILL TRANSITION INTO A NEWLY CREATED BOARD POSITION OF LEAD INDEPENDENT DIRECTOR.

CORMEDIX THERAPEUTICS ANNOUNCES LEADERSHIP AND BOARD UPDATES

 Q4 2025 UNAUDITED NET REVENUE OF APPROXIMATELY $127 MILLION   FY 2025 UNAUDITED PRO FORMA NET REVENUE OF APPROXIMATELY $400 MILLION   EXPECTS Q4 ADJUSTED EBITDA OF BETWEEN $77 MILLION AND $81 MILLION   UNAUDITED CASH AND SHORT-TERM INVESTMENTS OF APPROXIMATELY $148 MILLION  BERKELEY HEIGHTS, N.J., JAN. 08, 2026 (GLOBE NEWSWIRE) -- CORMEDIX THERAPEUTICS (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCES ITS PRELIMINARY UNAUDITED FOURTH QUARTER 2025 AND FULL-YEAR 2025 RESULTS, AND PROVIDES GUIDANCE AND AN UPDATE ON ITS BUSINESS.

CORMEDIX THERAPEUTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND PROVIDES BUSINESS UPDATES

BERKELEY HEIGHTS, N.J., DEC. 18, 2025 (GLOBE NEWSWIRE) -- CORMEDIX THERAPEUTICS (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED INTERIM RESULTS FOR THE COMPANY'S ONGOING REAL-WORLD EVIDENCE STUDY BEING CONDUCTED IN CONJUNCTION WITH U.S. RENAL CARE'S (USRC) USE OF DEFENCATH IN ADULT HEMODIALYSIS PATIENTS WITH CENTRAL VENOUS CATHETERS.

CORMEDIX THERAPEUTICS ANNOUNCES POSITIVE DATA FROM ONGOING REAL WORLD EVIDENCE STUDY OF DEFENCATH

CLOSED $17 MILLION FIRST TRANCHE FINANCING LED BY A STRATEGIC INVESTMENT FROM CORMEDIX, INC. CASH AND INVESTMENTS AT SEPTEMBER 30, 2025 WERE $21.3 MILLION; COMBINED WITH CONDITIONAL FUTURE TRANCHES OF PREVIOUS FINANCINGS, EXPECT SUFFICIENT CASH THROUGH A POTENTIAL PMA APPROVAL OF NIYAD IN LATE 2026 5 OF THE 9 TARGET PROFILE CLINICAL SITES ARE NOW ACTIVATED; COMPLETION OF NEPHRO STUDY EXPECTED IN H1 2026 CONFERENCE CALL AND WEBCAST TO BE HELD WEDNESDAY, NOVEMBER 12, 2025 AT 4:30 PM ET SAN MATEO, CALIF. , NOV. 12, 2025 /PRNEWSWIRE/ -- TALPHERA, INC. (NASDAQ: TLPH), ("TALPHERA"), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR USE IN MEDICALLY SUPERVISED SETTINGS, TODAY ANNOUNCED THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDED A CORPORATE UPDATE.

TALPHERA ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

 Q3 2025 NET REVENUE OF $104.3 MILLION; PRO FORMA NET REVENUE OF $130.8 MILLION   Q3 2025 NET INCOME OF $108.6 MILLION; ADJUSTED EBITDA OF $71.9 MILLION   FY 2025 PRO FORMA NET REVENUE GUIDANCE RAISED TO A RANGE OF $390 TO $410 MILLION   CONFERENCE CALL SCHEDULED FOR TODAY AT 8:30 A.M. EASTERN TIME  BERKELEY HEIGHTS, N.J.

CORMEDIX INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND UPDATES FY 2025 GUIDANCE

BERKELEY HEIGHTS, N.J., OCT. 31, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, BEFORE THE MARKET OPENS ON WEDNESDAY, NOVEMBER 12, 2025, AND WILL HOST A CORPORATE UPDATE CONFERENCE CALL AT 8:30AM EASTERN TIME.

CORMEDIX INC. TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 12, 2025

BERKELEY HEIGHTS, N.J., OCT. 23, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THAT DEFENCATH HAS RECEIVED AN INNOVATIVE TECHNOLOGY DESIGNATION FROM VIZIENT, THE LARGEST HEALTHCARE PERFORMANCE IMPROVEMENT COMPANY IN THE COUNTRY. CORMEDIX EXHIBITED DEFENCATH AT THE VIZIENT INNOVATIVE TECHNOLOGY EXCHANGE SEPTEMBER 17TH IN LAS VEGAS, NEVADA.

CORMEDIX INC. RECEIVES INNOVATIVE TECHNOLOGY DESIGNATION FROM VIZIENT FOR DEFENCATH

NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF CORMEDIX INC. (NASDAQ: CRMD) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. IF YOU CURRENTLY OWN CORMEDIX STOCK AND ACQUIRED SHARES ON OR BEFORE OCTOBER 16, 2019, YOU MAY BE ABLE TO SEEK CORPORATE GOVERNANCE REFORMS, THE RETURN OF FUNDS BACK TO THE COMPANY, A COURT-APPROVED FINANCIAL INCENTIVE AWARD, OR OTHER RELIEF AND BENEFITS. PLEASE CLICK HERE TO LEARN MORE.

HALPER SADEH LLC ENCOURAGES CORMEDIX INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

 Q3 2025 UNAUDITED PRO FORMA NET REVENUE OF MORE THAN $125 MILLION   Q3 2025 UNAUDITED DEFENCATH NET REVENUE OF MORE THAN $85 MILLION   RAISING FY 2025 PRO FORMA NET REVENUE GUIDANCE TO AT LEAST $375 MILLION   ~$30MM OF OPERATING SYNERGY ON A GO-FORWARD RUN-RATE BASIS BEFORE YEAR END 2025  BERKELEY HEIGHTS, N.J., OCT. 20, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED SELECTED PRELIMINARY UNAUDITED THIRD QUARTER RESULTS AND PROVIDED AN UPDATE ON ITS BUSINESS.

CORMEDIX INC. ANNOUNCES PRELIMINARY THIRD QUARTER 2025 RESULTS AND RAISES 2025 NET REVENUE GUIDANCE

- ENROLLMENT COMPLETED IN ONGOING PHASE III RESPECT STUDY IN PROPHYLAXIS OF FUNGAL INFECTIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC BLOOD AND MARROW TRANSPLANT -

CORMEDIX ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III RESPECT CLINICAL TRIAL FOR REZZAYO

BERKELEY HEIGHTS, N.J., SEPT. 08, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (CORMEDIX) (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THAT IT HAS MADE A $5 MILLION STRATEGIC MINORITY EQUITY INVESTMENT IN TALPHERA, INC. (NASDAQ: TLPH), ACQUIRING 9,090,909 SHARES AT AN AT-MARKET PRICE OF $0.55 PER SHARE AS PART OF TALPHERA'S CONCURRENTLY ANNOUNCED PRIVATE PLACEMENT FINANCING.

CORMEDIX ANNOUNCES STRATEGIC MINORITY INVESTMENT IN TALPHERA

CORMEDIX IS MAKING A STRATEGIC INVESTMENT IN TALPHERA AS THE LEAD INVESTOR, SUPPORTED BY EXISTING STOCKHOLDERS NANTAHALA, ROSALIND AND ROCK SPRINGS WITH SEVERAL NEW INSTITUTIONAL INVESTORS $17 MILLION IN PROCEEDS AT FIRST CLOSING WITH THE POTENTIAL TO RECEIVE AN ADDITIONAL $12 MILLION ACROSS ONE ADDITIONAL TRANCHE UPON THE ACHIEVEMENT OF THE PRIMARY ENDPOINT IN THE NEPHRO CLINICAL STUDY THE COMPLETION OF THIS FINANCING IS EXPECTED TO PROVIDE THE COMPANY WITH SUFFICIENT CAPITAL THROUGH THE PLANNED APPROVAL OF A NIYAD PMA IN THE SECOND HALF OF 2026 SAN MATEO, CALIF. , SEPT. 8, 2025 /PRNEWSWIRE/ --TALPHERA, INC.(NASDAQ: TLPH), (TALPHERA), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR USE IN MEDICALLY SUPERVISED SETTINGS, TODAY ANNOUNCED IT HAS ENTERED INTO SECURITIES PURCHASE AGREEMENTS WITH CORMEDIX INC. AND CERTAIN INSTITUTIONAL INVESTORS FOR THE SALE AND ISSUANCE OF SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS IN LIEU OF SHARES TO PURCHASE COMMON STOCK IN A PRIVATE PLACEMENT FOR TOTAL POTENTIAL PROCEEDS OF UP TO $29 MILLION.

CorMedix Inc.

CRMD

Price

Financial Reports

No items found.

Press Releases

CorMedix Inc.

CRMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CRMD